OBJECTIVE: Pulmonary arterial hypertension (PAH), associated with congenital heart disease (CHD), usually results from a systemic-to-pulmonary shunt. Eisenmenger syndrome (ES) is characterised by severe irreversible PAH and reversal of a previous systemic-to-pulmonary shunt. A national registry of ES patients was initiated to optimise patient care and to provide epidemiological information regarding PAH and CHD in Belgium. METHODS: All ES patients, older than 18 years, were selected through the local databases of ten centres in Belgium. After written informed consent, demographic, clinical, biochemical, technical, and treatment data were entered into the web-based registry. RESULTS: Ninety-one patients were included in the registry. Mean age was 36 +/- 11 years (range 18-59 years). Complete atrioventricular septal defect (N=26, 28.6%), followed by ventricular septal defect (N=25, 27.5%) were the commonest defects. Forty-five percent were patients with Down syndrome. Down patients were younger (32 +/- 9 versus 40 +/- 12 years; P = 0.039), had worse functional capacity (class II/III ratio: 15/16 versus 21/8; P = 0.035) and received significantly less specific PAH treatment (7% versus 38%; P = 0.002). CONCLUSION: Through the national Eisenmenger registry, 91 adult patients with ES were identified (estimated prevalence II per million inhabitants). Almost half of them were Down patients. Although having worse functional capacity, significantly less Down patients were receiving specific PAH treatment.
OBJECTIVE:Pulmonary arterial hypertension (PAH), associated with congenital heart disease (CHD), usually results from a systemic-to-pulmonary shunt. Eisenmenger syndrome (ES) is characterised by severe irreversible PAH and reversal of a previous systemic-to-pulmonary shunt. A national registry of ESpatients was initiated to optimise patient care and to provide epidemiological information regarding PAH and CHD in Belgium. METHODS: All ESpatients, older than 18 years, were selected through the local databases of ten centres in Belgium. After written informed consent, demographic, clinical, biochemical, technical, and treatment data were entered into the web-based registry. RESULTS: Ninety-one patients were included in the registry. Mean age was 36 +/- 11 years (range 18-59 years). Complete atrioventricular septal defect (N=26, 28.6%), followed by ventricular septal defect (N=25, 27.5%) were the commonest defects. Forty-five percent were patients with Down syndrome. Down patients were younger (32 +/- 9 versus 40 +/- 12 years; P = 0.039), had worse functional capacity (class II/III ratio: 15/16 versus 21/8; P = 0.035) and received significantly less specific PAH treatment (7% versus 38%; P = 0.002). CONCLUSION: Through the national Eisenmenger registry, 91 adult patients with ES were identified (estimated prevalence II per million inhabitants). Almost half of them were Down patients. Although having worse functional capacity, significantly less Down patients were receiving specific PAH treatment.
Authors: Christian Opitz; Ekkehard Grünig; Stephan Rosenkranz; Ann-Sophie Kaemmerer; Matthias Gorenflo; Dörte Huscher; David Pittrow; Peter Ewert; Christine Pausch; Marion Delcroix; Hossein A Ghofrani; Marius M Hoeper; Rainer Kozlik-Feldmann; Andris Skride; Gerd Stähler; Carmine Dario Vizza; Elena Jureviciene; Dovile Jancauskaite; Lina Gumbiene; Ralf Ewert; Ingo Dähnert; Matthias Held; Michael Halank; Dirk Skowasch; Hans Klose; Heinrike Wilkens; Katrin Milger; Christian Jux; Martin Koestenberger; Laura Scelsi; Eva Brunnemer; Michael Hofbeck; Silvia Ulrich; Anton Vonk Noordegraaf; Tobias J Lange; Leonhard Bruch; Stavros Konstantinides; Martin Claussen; Judith Löffler-Ragg; Hubert Wirtz; Christian Apitz; Rhoia Neidenbach; Sebastian Freilinger; Attila Nemes Journal: Cardiovasc Diagn Ther Date: 2021-12
Authors: Rachel Damico; Todd M Kolb; Lidenys Valera; Lan Wang; Traci Housten; Ryan J Tedford; David A Kass; Nicholas Rafaels; Li Gao; Kathleen C Barnes; Raymond L Benza; James L Rand; Rizwan Hamid; James E Loyd; Ivan M Robbins; Anna R Hemnes; Wendy K Chung; Eric D Austin; M Bradley Drummond; Stephen C Mathai; Paul M Hassoun Journal: Am J Respir Crit Care Med Date: 2015-01-15 Impact factor: 21.405
Authors: Michael A Gatzoulis; Michael Landzberg; Maurice Beghetti; Rolf M Berger; Michela Efficace; Sophie Gesang; Jian'guo He; Kelly Papadakis; Tomás Pulido; Nazzareno Galiè Journal: Circulation Date: 2019-01-02 Impact factor: 29.690
Authors: Harald Kaemmerer; Matthias Gorenflo; Dörte Huscher; David Pittrow; Christian Apitz; Helmut Baumgartner; Felix Berger; Leonhard Bruch; Eva Brunnemer; Werner Budts; Martin Claussen; Gerry Coghlan; Ingo Dähnert; Michele D'Alto; Marion Delcroix; Oliver Distler; Sven Dittrich; Daniel Dumitrescu; Ralf Ewert; Martin Faehling; Ingo Germund; Hossein Ardeschir Ghofrani; Christian Grohé; Karsten Grossekreymborg; Michael Halank; Georg Hansmann; Dominik Harzheim; Attila Nemes; Kalman Havasi; Matthias Held; Marius M Hoeper; Michael Hofbeck; Wolfgang Hohenfrost-Schmidt; Elena Jurevičienė; Lina Gumbienè; Hans-Joachim Kabitz; Hans Klose; Thomas Köhler; Stavros Konstantinides; Martin Köestenberger; Rainer Kozlik-Feldmann; Hans-Heiner Kramer; Cornelia Kropf-Sanchen; Astrid Lammers; Tobias Lange; Philipp Meyn; Oliver Miera; Katrin Milger-Kneidinger; Rhoia Neidenbach; Claus Neurohr; Christian Opitz; Christian Perings; Bjoern Andrew Remppis; Gabriele Riemekasten; Laura Scelsi; Werner Scholtz; Iveta Simkova; Dirk Skowasch; Andris Skride; Gerd Stähler; Brigitte Stiller; Iraklis Tsangaris; Carmine Dario Vizza; Anton Vonk Noordegraaf; Heinrike Wilkens; Hubert Wirtz; Gerhard-Paul Diller; Ekkehard Grünig; Stephan Rosenkranz Journal: J Clin Med Date: 2020-05-13 Impact factor: 4.241